GlassScriptPhysician profile
William Grant Willard, IV
NPI 1639158025
$1,113.98
in general payments reported to CMS, 2019-2025
21 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $152 · 2023: $158 · 2024: $250 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $198.06 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $167.86 | 2019-2025 | |
| Corium, LLC | $131.73 | 2023-2025 | Azstarys |
| Alk-Abello, INC | $102.46 | 2023-2025 | Grastek, Odactra, Neffy |
| Tris Pharma INC | $75.01 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $67.59 | 2020-2024 | Doc Band |
| Glaxosmithkline, LLC. | $43.16 | 2019-2023 | Bexsero |
| Neos Therapeutics, LP | $42.08 | 2019-2024 | Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2019-2020 | |
| Adlon Therapeutics L.P. | $32.00 | 2019-2020 | |
| Sanofi Pasteur INC. | $31.25 | 2020 | |
| Vertical Pharmaceuticals, LLC | $30.28 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $29.83 | 2024 | Qelbree |
| Merck Sharp & Dohme LLC | $25.99 | 2019-2023 | Proquad, Varivax, Gardasil 9 |
| Dermira, INC. | $23.47 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.54 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $16.55 | 2019 | |
| Mission Pharmacal Company | $13.82 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.62 | 2019 | |
| Genentech USA, INC. | $11.52 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Willard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.